Bristol-Myers To Purchase Medarex For $2.1B
In an effort to secure a top position in the biologics industry, Bristol-Myers Squibb Co. has agreed to buy Medarex Inc., which develops human antibody-based therapeutics to treat life-threatening diseases, in...To view the full article, register now.
Already a subscriber? Click here to view full article